Search - tctmd.com

Displaying 1 - 20 of 33

Sort: Relevancy | Date

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

News Conference News AHA 2024

ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS

Michael O'Riordan

November 21, 2024

Presentation AHA 2024

OptimiZation Of Lipid Lowering Therapies Using A Decision Support System In Patients With Acute Coronary Syndrome (ZODIAC): A Randomized Controlled Trial

Presenter: Kausik K. Ray

November 17, 2024

News Daily News

Rosuvastatin Bests Atorvastatin for Reducing CVD Risk: Registry Data

Michael O'Riordan

November 07, 2024

News Daily News

Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes

Michael O'Riordan

December 08, 2023

News Conference News EAS 2023

With New LDL Goalposts in FH, Combo Therapy Must Start Early

Michael O'Riordan

May 29, 2023

News Daily News

UK’s NICE Recommends Lower-Risk Thresholds for Statin Therapy

Michael O'Riordan

January 20, 2023

News Daily News

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Michael O'Riordan

January 16, 2023

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

News Conference News EAS 2022

Most Kids With FH Diagnosed by Cascade Screening, Albeit Late and Ineffectively

Michael O'Riordan

May 27, 2022

News Conference News EAS 2022

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Michael O'Riordan

May 24, 2022

News Conference News EAS 2022

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

Michael O'Riordan

May 24, 2022

News Daily News

British Medical Groups Express Concern About Inclisiran Rollout

Michael O'Riordan

December 14, 2021

News Daily News

Heterozygous FH Diagnosed Late, Remains Undertreated

Michael O'Riordan

September 13, 2021

News Conference News EAS 2021

For High-Risk Patients Getting Evolocumab in Europe, Other Meds Fall Short

Michael O'Riordan

June 03, 2021

News Conference News EAS 2020

Just One-Third of European Patients Get to LDL Cholesterol Goals

Michael O'Riordan

October 13, 2020

News Conference News EAS 2020

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

Michael O'Riordan

October 08, 2020

News Daily News

Increased Lifetime Exposure to High LDL Cholesterol Predicts ASCVD

Michael O'Riordan

September 22, 2020

News Daily News

Inclisiran Data in NEJM Prompt Talk of What Comes Next

Caitlin E. Cox

March 24, 2020

Advertisement

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS

OptimiZation Of Lipid Lowering Therapies Using A Decision Support System In Patients With Acute Coronary Syndrome (ZODIAC): A Randomized Controlled Trial

Rosuvastatin Bests Atorvastatin for Reducing CVD Risk: Registry Data

Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes

With New LDL Goalposts in FH, Combo Therapy Must Start Early

UK’s NICE Recommends Lower-Risk Thresholds for Statin Therapy

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Most Kids With FH Diagnosed by Cascade Screening, Albeit Late and Ineffectively

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

British Medical Groups Express Concern About Inclisiran Rollout

Heterozygous FH Diagnosed Late, Remains Undertreated

For High-Risk Patients Getting Evolocumab in Europe, Other Meds Fall Short

Just One-Third of European Patients Get to LDL Cholesterol Goals

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

Increased Lifetime Exposure to High LDL Cholesterol Predicts ASCVD

Inclisiran Data in NEJM Prompt Talk of What Comes Next

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content